Income Statement
CITIUS ONCOLOGY, INC.
CTOR
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Sep 30, 2025 2025 FY | Sep 30, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY |
|---|---|---|---|---|
|
Revenue
|
- | - | - | - |
|
Cost of Revenue
|
- | - | - | - |
|
Gross Profit
|
- | - | - | - |
|
Operating Expenses
|
23.52 | 20.57 | 1.01 | 0.14 |
|
Research & Development
|
6.42 | 4.93 | - | - |
|
Selling, General & Administrative
|
8.78 | 8.15 | 1.01 | 0.14 |
|
Other Operating Expenses
|
- | - | - | - |
|
Operating Income
|
-23.52 | -20.57 | -1.01 | -0.14 |
|
Non-Operating Income
|
-0.18 | 0.00 | 3.43 | 0.52 |
|
Interest Income
|
0.04 | - | - | - |
|
Interest Expense
|
0.22 | - | - | - |
|
Other Non-Op Income / Expense
|
- | - | - | - |
|
Income Before Tax
|
-23.70 | -20.57 | - | - |
|
Income Tax Expense
|
1.06 | 0.58 | - | - |
|
Non-Controlling Interest
|
- | - | - | - |
|
Net Income
|
-24.76 | -21.15 | 2.42 | 0.38 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Sep 30, 2025 2025 FY | Sep 30, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY |
|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - |
|
EBITDA
|
-23.52 | -20.57 | -1.01 | -0.14 |
|
Earnings Per Share (Basic)
|
-0.34 | -0.31 | 0.27 | 0.12 |
|
Diluted EPS
|
-0.34 | -0.31 | 0.27 | 0.12 |
|
Weighted Average Shares
|
73.27 | 68.05 | 6.60 | 1.87 |
|
Diluted Weighted Avg Shares
|
73.27 | 68.05 | 6.60 | 1.34 |
|
Comprehensive Income
|
- | - | - | - |